Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 26;13(2):125.
doi: 10.3390/vaccines13020125.

Vaccines in Dermatology-Present and Future: A Review

Eyan Goh  1 , Jean-Marc Chavatte  2 , Raymond T P Lin  2   3 , Lisa F P Ng  1   4   5 , Laurent Rénia  1   4   6 , Hazel H Oon  1   5   7
Affiliations
Review

Vaccines in Dermatology-Present and Future: A Review

Eyan Goh et al. Vaccines (Basel). .

Abstract

Dermatological vaccines have emerged as critical tools in preventing and managing a wide spectrum of skin conditions ranging from infectious diseases to malignancies. By synthesizing evidence from existing literature, this review aims to comprehensively evaluate the efficacy, safety, and immunogenicity of vaccines used in dermatology, including both approved vaccines and those currently being researched. Vaccines discussed in this paper include those targeting dermatoses and malignancies (e.g., acne vulgaris, atopic dermatitis, and melanoma); infectious diseases (e.g., human papillomavirus (HPV); varicella zoster virus (VZV); herpes zoster (HZ); warts; smallpox; mpox (monkeypox); hand, foot, and mouth disease (HFMD); candidiasis and Group B Streptococcus (GBS); and neglected tropical diseases (e.g., Buruli ulcer, leprosy, and leishmaniasis). Through this review, we aim to provide a detailed understanding of the role of vaccines in dermatology, identify knowledge gaps, and propose areas for future research.

Keywords: dermatology; immunization; vaccines.

PubMed Disclaimer

Conflict of interest statement

H.H.O. has served as a speaker, an advisory board member, and a researcher for AbbVie, Galderma, Janssen, and Novartis. She has also been a clinical investigator for La Roche Posay, Pfizer, and Sanofi; an advisory board member for Amgen; and a speaker and an advisory board member for Amgen, Boehringer Ingelheim, and Eli Lilly. The other authors declare no conflicts of interest.

References

    1. Vaccine-Preventable Diseases. [(accessed on 7 July 2024)]. Available online: https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases.
    1. Oon H.H., Lim D.Z.J., Barbieri J.S., Dréno B., Goh C.L., Layton A.M., Rocha M., See J.-A., Thiboutot D., Zouboulis C.C., et al. A Call for Action to Tackle the Increasing Global Burden and Challenges of Acne. J. Eur. Acad. Dermatol. Venereol. 2023;37:e1430–e1431. doi: 10.1111/jdv.19349. - DOI - PubMed
    1. Dreno B., Dekio I., Baldwin H., Demessant A.L., Dagnelie M.A., Khammari A., Corvec S. Acne microbiome: From phyla to phylotypes. J. Eur. Acad. Dermatol. Venereol. 2024;38:657–664. doi: 10.1111/jdv.19540. - DOI - PubMed
    1. McLaughlin J., Watterson S., Layton A.M., Bjourson A.J., Barnard E., McDowell A. Propionibacterium acnes and Acne Vulgaris: New Insights from the Integration of Population Genetic, Multi-Omic, Biochemical and Host-Microbe Studies. Microorganisms. 2019;7:128. doi: 10.3390/microorganisms7050128. - DOI - PMC - PubMed
    1. Lehmann H.P., Robinson K.A., Andrews J.S., Holloway V., Goodman S.N. Acne Therapy: A Methodologic Review. J. Am. Acad. Dermatol. 2002;47:231–240. doi: 10.1067/mjd.2002.120912. - DOI - PubMed

LinkOut - more resources